Viusid
Asset
- Stage
- Phase 3, no development reported
- Modality
- Supplement
- Target
- Not known
- 3
- Indications
- 38
- Trials
- 1
- Developer
No development reported since July 2009. Last activity: Trial NCT00502086 completed. clinicaltrials.gov
Indications
3Chronic hepatitis c
Phase 3, Completed, NCT00502086, clinicaltrials.gov, Nov 16, 2026
Cirrhosis
Phase 3, Completed, NCT00502086, clinicaltrials.gov, Nov 16, 2026
Metabolic dysfunction-associated steatohepatitis
Phase 3, Completed, NCT00509418, clinicaltrials.gov, Nov 16, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials38
- Evidence for its targets1
- Competitors12
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.